Cited by 2,217CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Open access

Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A., Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N., Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J., Rezvani, Katayoun·2020·New England Journal of Medicine

DOI 10.1056/nejmoa1910607PMC PMC7101242

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1910607

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citation
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 901–1,000 of 1,000

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 17
Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
Zhu, Y., Xiao, B., Zhang, J., Cui, X., Lu, Z., & Wu, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763806 · Cited by 17
Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions
Ligon, J. A., Wessel, K. M., Shah, N. N., & Glod, J. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846346 · Cited by 16
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
Yu, T., Yu, S.-K., Xiang, Y., Lu, K., & Sun, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.936496 · Cited by 18
Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
Du, Z., Zhu, S., Zhang, X., Gong, Z., & Wang, S. (2023) · Cancers · doi:10.3390/cancers15030567 · Cited by 17
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
Althaus, J., Nilius‐Eliliwi, V., Maghnouj, A., Döring, S., Schroers, R., Hudecek, M., Hahn, S. A., & Mika, T. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03443-1 · Cited by 19
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
Neo, S., Xu, S., Chong, J., Lam, K., & Wu, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006434 · Cited by 19
A promising target for breast cancer: B7-H3
Jiang, Y., Liu, J., Chen, L., Qian, Z., & Zhang, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-11933-3 · Cited by 18
Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma
Lin, X., Guan, T., Li, Y., Lin, Y., Huang, G., Lin, Y., Sun, P., Li, C., Gu, J., Zeng, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1337557 · Cited by 18
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy
Huang, J., Yang, Q., Wang, W., & Huang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378739 · Cited by 18
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00568 · Cited by 20
IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy
Biggi, A. F. B., Silvestre, R. N., Tirapelle, M. C., de Azevedo, J. T. C., García, H. D. M., dos Santos, M. H., de Lima, S. C. G., de Souza, L. E. B., Covas, D. T., Malmegrim, K. C. R., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.001 · Cited by 17
Purification, Culture, and CD19‐CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells
Herrera, L., Juan, M., & Eguizábal, C. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.108 · Cited by 17
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation
Pegoraro, F., & Favre, C. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04433-y · Cited by 17
T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14871 · Cited by 21
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions
Tawfik, E. A., Aldrak, N. A., Albrahim, S. H., Alzahrani, D. A., Alfassam, H. A., Alkoblan, S. M., Almalik, A., Chen, K., Abou-Khalil, R., Shah, K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0065 · Cited by 18
NK cell upraise in the dark world of cancer stem cells
Shokouhifar, A., Firouzi, J., Nouri, M., Sarab, G. A., & Ebrahimi, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02400-1 · Cited by 17
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
Khurana, A., & Lin, Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00920-6 · Cited by 17
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Chu, Y., Lamb, M. G., Cairo, M. S., & Lee, D. A. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00932-2 · Cited by 17
Bringing natural killer cells to the clinic
Chiossone, L., & Vivier, É. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220830 · Cited by 17
Cell-based immunotherapy in gynecologic malignancies
Schaar, B. T., Krishnan, V., Tallapragada, S., & Dorigo, O. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000433 · Cited by 17
Presetting CAR-T cells during ex vivo biomanufacturing
Wang, X., Liao, Y., Liu, D., Zheng, J., & Shi, M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.031 · Cited by 19
Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions
Ruan, L., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530541 · Cited by 16
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression
Röder, J., Alekseeva, T., Kiefer, A., Kühnel, I., Prüfer, M., Zhang, C., Bodden, M., Rosigkeit, S., Waldmann, A., Tonn, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.033 · Cited by 16
Recent advances in tumor immunotherapy based on NK cells
Chen, M., Zhang, B., Mu, X. N., Zhang, B., Yang, T., Zhang, G., Gu, Y., Pei, B., & Liang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1595533 · Cited by 18
Multiplexed iPSC platform for advanced NK cell immunotherapies
Kumar, A., Fischer, C., Cichocki, F. M., & Miller, J. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102282 · Cited by 18
Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies
Lafuente‐Gómez, N., Kang, S. J., & Mooney, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02008-w · Cited by 22
Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells
Xu, X., Cao, P., Wang, M., Wan, Y., Sun, S.-W., Chen, Y., Liu, Y., Su, T., Gao, G., Liu, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658580 · Cited by 16
Self-citation
The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies
Zhu, W., Fan, C., Zhao, Y., Li, W., Niu, J., Dong, S., Yang, Z., & Zhou, W. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03980-y · Cited by 17
Challenges and opportunities of human iPSC-derived NK as “Off-the-shelf” cellular therapies
Romanini, N., Netsrithong, R., Themeli, M., & Tazzari, M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03558-6 · Cited by 18
Cord blood beyond transplantation: can we use the experience to advance all cell therapies?
Scaradavou, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17297 · Cited by 16
Clinical experience of CAR T cells for multiple myeloma
Simmons, G. L., Satta, T., & Puglianini, O. A. C. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101306 · Cited by 16
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
Heyman, B. M., Tzachanis, D., & Kipps, T. J. (2022) · Cancers · doi:10.3390/cancers14071715 · Cited by 17
Application and Design of Switches Used in CAR
Głowacki, P., & Rieske, P. (2022) · Cells · doi:10.3390/cells11121910 · Cited by 18
Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populations
Allan, D., Wu, C., Mortlock, R. D., Chakraborty, M., Rezvani, K., Davidson-Moncada, J. K., Dunbar, C. E., & Childs, R. W. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.12.006 · Cited by 16
Self-citation
Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Wang, Z., Li, W., Dong, H., & Han, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1077436 · Cited by 16
Generalized phase I‐II designs to increase long term therapeutic success rate
Thall, P. F., Zang, Y., & Yuan, Y. (2023) · Pharmaceutical Statistics · doi:10.1002/pst.2301 · Cited by 16
Self-citation
Process engineering of natural killer cell-based immunotherapy
Motallebnejad, P., Kantardjieff, A., Cichocki, F. M., Azarin, S. M., & Hu, W. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.03.018 · Cited by 16
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
Kumar, A., Khani, A. T., Duault, C., Aramburo, S., Ortiz, A. S., Lee, S. J., Chan, A., McDonald, T., Huang, M., Lacayo, N. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006649 · Cited by 16
CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Liu, T., Dai, X., Xu, Y., Guan, T., Hong, L., Zaib, T., Zhou, Q., Cheng, K., Zhou, X., Ma, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04409-8 · Cited by 16
Killer instincts: natural killer cells as multifactorial cancer immunotherapy
Nersesian, S., Carter, E. B., Lee, S. N., Westhaver, L. P., & Boudreau, J. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269614 · Cited by 20
Allogeneic CAR T Cell Therapy for Cancer
Sasu, B. J., Lauron, E. J., Schulz, T. F., Cheng, H., & Sommer, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-023316 · Cited by 16
Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma
Yu, T., Xu-Monette, Z. Y., Lagoo, A. S., Shuai, W., Wang, B., Neff, J., Carrillo, L. F., Carlsen, E. D., Piña‐Oviedo, S., & Young, K. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1335689 · Cited by 16
A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases
Hassan, S. H., Alshahrani, M. Y., Saleh, R. O., Mohammed, B. A., Kumar, A., Almalki, S. G., Alkhafaji, A. T., Ghildiyal, P., Al-Tameemi, A. R., & Elawady, A. (2024) · Medical Oncology · doi:10.1007/s12032-024-02362-0 · Cited by 17
The investigation of oncolytic viruses in the field of cancer therapy
Yuan, Z., Zhang, Y., Wang, X., Wang, X., Ren, S., He, X., Su, J., Zheng, A., Guo, S., Chen, Y., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1423143 · Cited by 18
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies
Chandra, D. J., Alber, B., & Saultz, J. N. (2024) · Cancers · doi:10.3390/cancers16152615 · Cited by 17
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review
Tang, C., & Zhang, Y. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155518 · Cited by 19
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
Luo, W., Hoang, H., Zhu, H., Miller, K. E., Mo, X. M., Eguchi, S., Tian, M., Liao, Y., Ayello, J., Rosenblum, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009726 · Cited by 16
The rewired immune microenvironment in leukemia
Ciantra, Z. B., Paraskevopoulou, V., & Aifantis, I. (2025) · Nature Immunology · doi:10.1038/s41590-025-02096-9 · Cited by 19
Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery
Kim, H., Lee, M. K., Han, B., Kim, J.-H., Cho, D., Doh, J., & Chung, A. J. (2025) · Advanced Science · doi:10.1002/advs.202412544 · Cited by 16
Harnessing Natural Killer Cell Function for Genitourinary Cancers
Bhardwaj, N., Farkas, A. M., Gul, Z., & Sfakianos, J. P. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.002 · Cited by 16
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy
Iovino, L., Thur, L. A., Gnjatic, S., Chapuis, A. G., Milano, F., & Hill, J. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002392 · Cited by 17
Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy
Choi, S. H., Kim, H. J., Park, J. D., Ko, E.-S., Lee, M., Lee, D.-K., Choi, J., Jang, H. J., Kim, I., Jung, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004964 · Cited by 16
Deciphering the localization and trajectory of human natural killer cell development
Hegewisch-Solloa, E., Nalin, A. P., Freud, A. G., & Mace, E. M. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad027 · Cited by 17
Resting natural killer cells promote the progress of colon cancer liver metastasis by elevating tumor-derived stem cell factorPreprint
Mao, C., Chen, Y., Xing, D., Zhang, T., Lin, Y., Long, C., Yu, J., Luo, Y., Ming, T., Mei, D., et al. (2024) · eLife · doi:10.7554/elife.97201 · Cited by 17
CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases
Yang, Z., Liu, Y., & Hai, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122556 · Cited by 16
Enhancing NK Cell Antitumor Activity With Natural Compounds: Research Advances and Molecular Mechanisms
Wu, Y., Yin, M., Xia, W., Dou, B., Liu, X., & Sun, R. (2025) · Phytotherapy Research · doi:10.1002/ptr.8456 · Cited by 14
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 16
CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
Narkhede, M. S., Mehta, A., Ansell, S. M., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5546 · Cited by 19
A Hot Topic: Cancer Immunotherapy and Natural Killer Cells
Michel, T., Ollert, M. W., & Zimmer, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020797 · Cited by 15
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Sun, K.-H., Wong, Y.-T., Cheung, K. M., Yuen, C. M., Chan, Y.-T., Lai, W.-Y. (., Chao, C. (., Fan, W.-S., Chow, Y.-K., Law, M. F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020409 · Cited by 15
The application of mechanobiotechnology for immuno-engineering and cancer immunotherapy
Yoon, C. W., Pan, Y., & Wang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1064484 · Cited by 14
Single‐Cell Profiling Reveals Functional Heterogeneity and Serial Killing in Human Peripheral and Ex Vivo‐Generated CD34+ Progenitor‐Derived Natural Killer Cells
Subedi, N., Verhagen, L. P., de Jonge, P. K. J. D., Eyndhoven, L. C. V., van Turnhout, M. C., Koomen, V., Baudry, J., Eyer, K., Dolstra, H., & Tel, J. (2022) · Advanced Biology · doi:10.1002/adbi.202200207 · Cited by 15
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
Piccinelli, S., Romee, R., & Shapiro, R. M. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.02.002 · Cited by 15
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
Kim, H., Han, M., Kim, M., Kim, H., Im, H. J., Kim, N., & Koh, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.13822 · Cited by 15
Molecular imaging of innate immunity and immunotherapy
Xia, W., Singh, N., Goel, S., & Shi, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114865 · Cited by 15
Update of Natural Products and Their Derivatives Targeting Epstein–Barr Infection
Pennisi, R., Trischitta, P., Costa, M. D. A., Venuti, A., Tamburello, M. P., & Sciortino, M. T. (2024) · Viruses · doi:10.3390/v16010124 · Cited by 15
Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need
Zygmunciak, P., Robak, T., & Puła, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031589 · Cited by 18
Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma
Lin, X., Guan, T., Xu, Y., Li, Y., Lin, Y., Chen, S., Chen, Y., Wei, X., Li, D., Cui, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1337489 · Cited by 17
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 17
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Zu, Y., Ren, Q., Zhang, J., Su, H., Lu, Q., Song, Y., & Zhou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00577-5 · Cited by 15
Harnessing Natural Killer Cell Innate and Adaptive Traits in HIV Infection
Alrubayyi, A., Ogbe, A., Cubero, E. M., & Peppa, D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00395 · Cited by 16
Harnessing the Immune System to Fight Multiple Myeloma
Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021) · Cancers · doi:10.3390/cancers13184546 · Cited by 16
From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
Voynova, E., & Kovalovsky, D. (2021) · Cells · doi:10.3390/cells10112845 · Cited by 15
The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?
da Silva, L. H. R., Catharino, L. C. C., da Silva, V. J., Evangelista, G. C. M., & Barbuto, J. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020400 · Cited by 16
SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium
Shim, S., Tufa, D. M., Woods, R., George, T. D., Shank, T., Yingst, A. M., Lake, J. A., Cobb, L. M., Jones, D., Jones, K. L., et al. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac012 · Cited by 15
Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin
Sun, Y., Zhou, J. H. S., & Jiang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842831 · Cited by 16
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
Kim, N., Lee, D.-H., Choi, W. S., Yi, E., Kim, H., Kim, J. M., Jin, H., & Kim, H. S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.214 · Cited by 15
Optimizing CAR T cell therapy in lymphoma
Qualls, D. A., & Salles, G. A. (2021) · Hematological Oncology · doi:10.1002/hon.2844 · Cited by 16
CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK CellsPreprint
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Devin, R. D., Lyberger, J. M., Behbehani, G. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.17.435886 · Cited by 15
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
Rassek, K., Misiak, J., Ołdak, T., Rozwadowska, N., Basak, G. W., & Kolanowski, T. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561174 · Cited by 14
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond
Li, Y., Liu, Y., & Lin, X. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01304-8 · Cited by 17
Cell-Based Therapies for Solid Tumors: Challenges and Advances
Smolarska, A., Kokoszka, Z., Naliwajko, M., Strupczewska, J., Tondera, J., Wiater, M., & Orzechowska, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125524 · Cited by 15
Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature
Wang, X., Luo, W., Chen, Z., Li, C., Zhou, J., Huang, Z., Tang, L., Wu, J., Wu, Z., Li, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010822 · Cited by 16
CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies
Zhang, W., Yang, L.-Y., & Fan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622433 · Cited by 14
Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks
Baughan, S. L., Folsom, T. D., Johnson, M., Kreuger, J., Webber, B. R., & Moriarity, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704404 · Cited by 17
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy
An, M., Yan, J., Liu, B., & Liu, Q. (2026) · 癌症：英文版 · doi:10.34133/cancomm.0023 · Cited by 17
NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors
Tomaipitinca, L., Russo, E., & Bernardini, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100968 · Cited by 14
Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer
Tang, L., Shao, H., Wu, Y., Wang, J., Qian, X., He, L., Huang, H., & Xu, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110807 · Cited by 14
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
Vu, S. H., Pham, H. H., Pham, T. T. P., Le, T. T., Vo, M.-C., Jung, S., Lee, J., & Nguyen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275076 · Cited by 14
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Wang, Y., Jin, S., Zhuang, Q., Liu, N., Chen, R., Adam, S. A., Jin, J., & Sun, J. (2023) · MedComm · doi:10.1002/mco2.422 · Cited by 17
Natural killer cells at the forefront of cancer immunotherapy with immune potency, genetic engineering, and nanotechnology
Pan, W., Tao, T., Qiu, Y., Zhu, X. M., & Zhou, X. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104231 · Cited by 16
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Esmaeilzadeh, A., Hadiloo, K., Jabbari, M., & Elahi, R. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122381 · Cited by 17
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells
Renner, A., Stahringer, A., Ruppel, K. E., Fricke, S., Koehl, U., & Schmiedel, D. (2024) · Gene Therapy · doi:10.1038/s41434-024-00454-0 · Cited by 15
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations
Martín-Antonio, B., Blanco, B., González‐Murillo, Á., Hidalgo, L., Minguillón, J., & Pérez-Chacón, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386856 · Cited by 14
Click Chemistry‐Mediated Polymannose Surface‐Engineering of Natural Killer Cells for Immunotherapy of Triple‐Negative Breast Cancer
Niu, X., He, Y., Guo, J., Yao, L., Wang, Y., Yu, W., Liu, Z., & Chen, H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400970 · Cited by 14
Generation of non-genetically modified, CAR-like, NK cells
Coënon, L., Rigal, É., Courot, H., Multrier, C., Zemiti, S., Lambour, J., Pugnière, M., de Toledo, M., Bossis, G., Cartron, G., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009070 · Cited by 14
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives
Radoš, M., Landegger, A., Schmutzler, L., Rabidou, K., Taschner‐Mandl, S., & Fetahu, I. S. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10212-8 · Cited by 18
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15

Authors: Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
ORCID: Liu, Enli
Banerjee, Pinaki
Macapinlac, Homer A.
Thompson, Philip
Thall, Peter
Kaplan, Mecit
Cao, Kai
Daher, May
Hosing, Chitra
Cohen, Evan N.
Kebriaei, Partow
Mehta, Rohtesh
Neelapu, Sattva
Nieto, Yago
Wang, Michael
Wierda, William
Keating, Michael
Champlin, Richard
Shpall, Elizabeth J.
Rezvani, Katayoun
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-02-06
Volume: 382
Issue: 6
Pages: 545-553
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1910607
PMC: PMC7101242
OpenAlex: W3004611567
Cited by: 2,217
References: 37
Citations by year: 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
FWCI: 113.83
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
MeSH terms: Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks